Search Results - combination

34 Results

Sort By:

Induction of Synthetic Lethality with Epigenetic Therapy (ISLET) by Combined DNA Methyltransferase and Aurora Kinase Inhibition

Invention NoveltyThis invention is a novel paradigm for the induction of synthetic lethality through epigenetic modulations. This can induce functionality and efficacy of therapeutics against cancer cells that may have resistance to each therapeutic alone. Value PropositionThe complex and adaptive nature of the host of diseases termed cancer poses significant...

Published: 5/9/2024 | Inventor(s): Srinivasan Yegnasubramanian, William Nelson, Ajay Vaghasia, Philipp Nuhn

Keywords(s): Cancers, Chemotherapy/Targeted Therapy, Combination, Disease Indication, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities

M4N and Temozolomide Combination Therapy for Glioblastoma multiforme (GBM)

Unmet NeedGlioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults and remains one of the most aggressive types of malignancies. The mainstay of GBM treatment is surgery, radiation and adjuvant chemotherapy using temozolomide (TMZ). While treatment options have incrementally improved, survival rates remains dismal. Only...

Published: 5/9/2024 | Inventor(s): Ru Chih Huang, Jong ho Chun, Yu-Ling Lin, Yu-Chuan Liang, Kuang-Wen Liao, Tiffany Jackson, David Mold, Chien-Hsien Lai

Keywords(s): Agonists/Promoters, Brain Cancer, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Glioblastoma, Glioma, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Brain Cancer

Targeting PTPN22 in Cancer Therapy

Unmet NeedTumor-infiltrating lymphocytes (TILs) such as B-cells, T-cells, and natural killers are gaining traction in anti-tumor immune responses. TILs involve the use of special immune cells called T-cells, otherwise known as lymphocytes, which protect the body from viral infections, fight cancer, and coordinate the activities of other cells during...

Published: 5/9/2024 | Inventor(s): Elizabeth Jaffee, Won Jin Ho, Soren Charmsaz

Keywords(s): Cancers, Combination, Discovery/Research Tools, Disease Indication, In Vivo Research Tool, Knock Out Mouse Model, Mouse Model, Target, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Research Tools > Animal Models

Use of Combination Retinoic Acid and dsRNA Products for Skin Rejuvenation

Unmet NeedGlobally, the anti-aging cosmetic treatment market is projected to grow to $57.5B dollars in 2020. Currently, one of the leading the leading topical ingredients in anti-aging creams for wrinkle reduction is retinoids, which are derivatives of vitamin A. Retinoic acid, the active metabolite of retinoids, has been shown to help repair sun damaged...

Published: 5/9/2024 | Inventor(s): Luis Garza, Dongwon Kim

Keywords(s): Biologics, Chemotherapy/Immunotherapy, Combination, Disease Indication, Nucleic Acid, Skin Disorders, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Wound Healing

Category(s): Technology Classifications > Therapeutic Modalities

Leptin Prevents Opiate-induced Respiratory Depression

Description:Unmet Need The opioid epidemic continues to be a public health crisis, with about 130 Americans dying every day from an opioid overdose. Opiate-mediated respiratory suppression (ORS) is the primary cause of opiate-associated deaths, and obesity greatly increases opiate-related mortality. Obesity also contributes to obstructive sleep apnea...

Published: 5/9/2024 | Inventor(s): Vsevolod Polotsky, David Mendelowitz, Carla Freire

Keywords(s): Biologics, Combination, Drug Delivery Mechanism, Intranasal Administration, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Respiratory Diseases

Compositions and Methods for Treating Melanoma--Further Modifications

Unmet NeedTherapeutic cancer vaccines aim to activate the antitumor T cell response. These vaccines are designed to prime naïve antitumor T cells, by activating antigen presenting cells, particularly dendritic cells (DCs). DNA-based cancer vaccines are a particularly promising approach, partially due to the ease with which they can be manufactured....

Published: 5/9/2024 | Inventor(s): Richard Markham, James Gordy

Keywords(s): Biologics, Cancers, Combination, Disease Indication, Melanoma, Skin Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Vaccine

Category(s): Clinical and Disease Specializations > Oncology > Melanoma, Clinical and Disease Specializations > Dermatology, Clinical and Disease Specializations > Oncology > Skin Cancer, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines

Administration of DNA Vaccines with DNA Encoding Ii-PADRE Generates Potent PADRE-specific CD4+ T-cell Immune Responses and Enhances Vaccine Potency

Unmet Need: DNA vaccine technology is a desirable antiviral and cancer immunotherapeutic strategy for its simple design and cost-effective implementation. However, current DNA vaccine programs are hindered by poor immunogenicity. Technical Details: Johns Hopkins researchers have designed a novel fusion construct to enhance immunogenicity to DNA vaccines....

Published: 5/9/2024 | Inventor(s): Chien-Fu Hung, T.c. Wu

Keywords(s): Cancers, Combination, Disease Indication, Immunotherapy/ Immunotherapy, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities

Low Dose Adjuvant Epigenetic Modifiers Inhibit Cancer Lung Metastases through Disruption of the Myeloid Environment in Pre-metastatic Niches

Unmet NeedCancer recurrence, even following complete surgical resection, remains a large unmet clinical problem. In non-small cell lung cancer (NSCLC) patients, recurrence following surgery remains 30-70%, and the five-year survival rate remains 23% with over 140,000 deaths occurring each year. Recurrence post-surgery can be driven by a number of factors,...

Published: 5/9/2024 | Inventor(s): Malcolm Brock, Zhihao Lu

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Chemotherapy, Combination, Disease Indication, Non-novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Oncology > Lung Cancer, Technology Classifications > Therapeutic Modalities > Small Molecules

New Method of mTOR Regulation by TSC2 Modification

Unmet NeedImmunotherapies that boost T cell responses have demonstrated therapeutic efficacy in numerous cancers. To improve the efficacy and expand the clinical utility of immunotherapy, improved methods of stimulating T cell responses are needed. mTORC1 is a critical regulator of T cell activation, differentiation and function. While modulating mTORC1...

Published: 5/9/2024 | Inventor(s): David Kass, Mark Ranek, Kristen Kokkonen, Jonathan Powell, Chirag Patel

Keywords(s): Cancers, Cell Therapy/Gene Therapy, Combination, Disease Indication, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities

Non-immunosuppressive FK506 analogs and use thereof

Unmet NeedChronic, nonhealing wounds are estimated to affect approximately 2% of the general population, and the cost of caring for these wounds exceeds $50 billion per year. These costs are expected to rise due to the increasing prevalence of diabetes and other diseases that hinder wound healing. Chronic infections increase morbidity and mortality...

Published: 5/9/2024 | Inventor(s): Jun Liu, Zhaoli Sun, Brandon Peiffer, Yuefan Wang, Le Qi, Zufeng Guo, Hanjing Peng, Ali Ahmadi

Keywords(s): Antagonists/Inhibitors, Combination, Disease Indication, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutic Substance Synthesis Method, Therapeutics, Therapy Type, Transplants

Category(s): Clinical and Disease Specializations > Wound Healing, Technology Classifications > Therapeutic Modalities > Small Molecules

1 2 3 4